Table 3.
Pancreatic ductal adenocarcinoma trials involving agents that target DNA repair
|
Drug
|
Target
|
Trial description
|
NCI trial number
|
| M6620 (VX-970) | ATR | Phase I, M6620 and irinotecan hydrochloride in treating patients with solid tumors that are metastatic or cannot be removed by surgery | NCT02595931 |
| AZD6738/olaparib | ATR/PARP | Phase II, Phase II trial of AZD6738 alone and in combination with olaparib | NCT03682289 |
| BAY1895344 | ATR | Phase I, testing the addition of an anti-cancer drug, BAY 1895344 ATR inhibitor, to the chemotherapy treatment (Gemcitabine) for advanced solid tumors, pancreatic cancer, and ovarian cancer | NCT04616534 |
| Olaparib | PARP | Phase II, a study of pembrolizumab and olaparib for people with metastatic pancreatic ductal adenocarcinoma and homologous recombination deficiency or exceptional treatment response to platinum-based therapy | NCT04666740 |
| Olaparib | PARP | Phase I, targeted PARP or MEK/ERK inhibition in patients with pancreatic cancer | NCT04005690 |
| Olaparib | PARP | Phase II, a phase 2 study of cediranib in combination with olaparib in advanced solid tumors | NCT02498613 |
| Olaparib | PARP | Phase II, olaparib in treating patients with stage IV pancreatic cancer | NCT02677038 |
| Talazoparib | PARP | Phase II, measuring the effects of talazoparib in patients with advanced cancer and DNA repair variations | NCT04550494 |
| Talazoparib | PARP | Phase I/II, a study of avelumab, binimetinib and talazoparib in patients with locally advanced or metastatic RAS-mutant solid tumors | NCT03637491 |
| Niraparib | PARP | Phase II, niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial | NCT03553004 |
| Niraparib | PARP | Phase II, niraparib in patients with pancreatic cancer | NCT03601923 |
| Rucaparib | PARP | Phase II, maintenance rucaparib in BRCA1, BRCA2 or PALB2 mutated pancreatic cancer that has not progressed on platinum-based therapy | NCT03140670 |
| MK1775 | WEE1 | Phase I/II, a phase i and randomized phase II study of nab-paclitaxel/gemcitabine with or without AZD1775 for treatment of metastatic adenocarcinoma of the pancreas | NCT02194829 |
PARP: Poly (ADP ribose) polymerase.